Reckitt Benckiser Group (LON:RKT) Shares Up 0.3% – Should You Buy?

Shares of Reckitt Benckiser Group plc (LON:RKT) rose 0.3% on Tuesday . The stock traded as high as GBX 5,354 ($67.54) and last traded at GBX 5,338 ($67.34). Approximately 1,126,737 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 3,728,999 shares. The stock had previously closed at GBX 5,324 ($67.16).

Analyst Ratings Changes

Separately, Berenberg Bank decreased their price objective on Reckitt Benckiser Group from GBX 5,200 ($65.60) to GBX 5,177 ($65.31) and set a “hold” rating on the stock in a research report on Wednesday, October 23rd.

Reckitt Benckiser Group Stock Up 0.3 %

The firm’s 50 day moving average price is GBX 5,009.78 and its 200-day moving average price is GBX 4,744.93. The company has a current ratio of 0.69, a quick ratio of 0.46 and a debt-to-equity ratio of 110.26. The company has a market cap of £36.53 billion, a P/E ratio of 24.50, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09.

Insider Buying and Selling at Reckitt Benckiser Group

In other Reckitt Benckiser Group news, insider Shannon Eisenhardt sold 1,368 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of GBX 4,723 ($59.58), for a total value of £64,610.64 ($81,507.05). Insiders own 0.05% of the company’s stock.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.